David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses promising results from the ongoing Phase II ELARA trial (NCT03568461) investigating the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (tisa-cel) for follicular lymphoma. Early data has shown that tisa-cel is well-tolerated and achieves durable complete remissions. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.